A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients - TRIUMPH

ALEXION PHARMACEUTICALS INCORPORATED0 个研究点目标入组 109 人开始时间: 2005年2月14日最近更新: 2019年11月25日

试验速览

暂无简介。

•1. Individuals at least 18 years of age
•2. Patients must have required at least 4 episodes of transfusions in the 12 months prior to Visit 1 for anemia or anemia-related symptoms
•3. Presence of a GPI deficient red blood cell clone (type III cells) by flow cytometry equal to or greater than 10%
•4. Patients taking erythropoeitin must be on a stable dose for 26 weeks prior to Visit 1 and the dose must be expected to remain stable during the observation period and the treatment phase
•5. Patients taking immunosuppressants must be on a stable dose for at least 26 weeks prior to visit 1 and the dose must be expected to rermain stable during the Observation Period and the Treatment Phase
•6. Other criteria specified in the Protocol
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Patients whose mean hemoglobin levels prior to transfusion over the previous 12 months is greater than 10.5 gm/dL
•2. Absolute neutrophil count < 500 per microlitre
•3. Presence or suspicion of active bacterial infection in the opinion of the investigator, at Visit 3 or recurrent bacterial infections
•4. Known or suspected hereditary complement deficiency
•5. Participation in any other drug trial or exposure to other investigational agent, device, or procedure within 30 days prior to Visit 1
•6. Pregnant, breast-feeding or intending to conceive during the course of the study, including the post-treatment phase
•7. Any of the criteria stated in the Protocol

发起方

ALEXION PHARMACEUTICALS INCORPORATED